A Phase I, Single Centre, Randomised, Single Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Inhaled AZD8871 in Healthy Male Japanese Subjects.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs AZD 8871 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 22 Sep 2017 Planned End Date changed from 10 Oct 2017 to 4 Oct 2017.
- 22 Sep 2017 Planned primary completion date changed from 10 Oct 2017 to 4 Oct 2017.
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.